Academic literature on the topic 'DIABETIC NEUROPATHIC PAIN'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'DIABETIC NEUROPATHIC PAIN.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "DIABETIC NEUROPATHIC PAIN"
1
Rachmantoko, Reza, Zamroni Afif, Dessika Rahmawati, Rodhiyan Rakhmatiar, and Shahdevi Nandar Kurniawan. "DIABETIC NEUROPATHIC PAIN." JPHV (Journal of Pain, Vertigo and Headache) 2, no. 1 (March 1, 2021): 8–12. http://dx.doi.org/10.21776/ub.jphv.2021.002.01.3.
Full textAbstract:
Diabetic Neuropathy is the most common complication from diabetes, which experienced in almost 90% diabetes patient. Evenly pain is one of the most common symptoms of diabetic neuropathic, but the pathophysiology mechanism of pain is not clearly known. The hyptosesis of toxicity of hyperglycemia on development of pain complication has been widely accepted globally, but there is other proposed hypothesis. Basic concept in management of painful diabetic neuropathic is exclusion of the other cause of painful peripheral neuropathy, improving glycemic control for prophylaxis therapy and medication use for alleviating pain. The first choice drug of therapy for alleviating pain are anticonvulsant, like pregabalin and gabapentin, and antidepressant, mainly that work on inhibiting serotonine and noradrenaline reuptake. In conclusion, the better understanding of painful diabetic neuropathic underlying mechanism can help to find a better management that improving the guideline quality in optimalizing pain control.
2
Pebrianti, Sandra, Bambang Aditya Nugraha, and Iwan Shalahuddin. "Manajemen nyeri neuropati pada pasien diabetes melitus tipe 2: Studi literatur." Holistik Jurnal Kesehatan 14, no. 2 (July 27, 2020): 276–82. http://dx.doi.org/10.33024/hjk.v14i2.2828.
Full textAbstract:
Management of neuropathic pain in patients with diabetes mellitus patients type 2: A literature studyBackground: An increase in the population of people with diabetes mellitus (DM), has an impact on increasing the most serious complications of diabetic neuropathy. Studies reveal that 16% to 26% of patients with diabetes neuropathy experience pain. People with DM who experience diabetic neuropathy pain will feel very uncomfortable and disturbed, neuropathic pain causes complaints not only physically, but also the mood and quality of life of patients. Therefore, it is important to identify the management of neuropathic pain in patients with type 2 diabetes mellitus to improve the quality of life of patients.Purpose: This literature review is to identify the management of neuropathic pain in type 2 DM patients.Method: Tracking this literature review using databases such as Google Scholar, Pubmed and Proquest with inclusion criteria that focus on the management of neuropathic pain in DM patients, publication years between 2010-2020 in Indonesian and English, quasi experiment design and Randomized controlled trial . Obtained as many as 87 articles, 32 met the criteria of the year and as many as 19 were the last complete articles found as many as 10 articles which were in line with the focus of the search.Results: Neuropathy management interventions were grouped into exercise, relaxation distraction techniques, percutaneous electrical stimulation and supportive education.Conclusion: Exercise, relaxation distraction techniques, percutaneous electrical stimulation and educational supportive interventions become one of the interventions that can be considered to use in the management of neuropathic pain in type 2 diabetes mellitus patients to improve comfort and quality of life.Keyword: Management; Neuropathic Pain; Patients; Diabetes mellitus type 2Pendahuluan: Peningkatan populasi penyandang diabetes melitus (DM), berdampak pada peningkatan komplikasi yang paling serius yaitu neuropati diabetik. Studi mengungkapkan bahwa 16% hingga 26% pasien dengan neuropati diabetes mengalami rasa nyeri. Penyandang DM yang mengalami nyeri neuropati diabetik akan merasa sangat tidak nyaman dan terganggu, nyeri neuropati menimbulkan keluhan tidak hanya fisik, namun juga mood dan kualitas hidup pasien. Oleh karena itu, menjadi penting untuk mengidentifikasi manajemen nyeri neuropati pada psien diabetes mellitus tipe 2 untuk meningkatkan kualitas hidup pasien.Tujuan: Dengan studi literatur untuk mengidentifikasi manajemen nyeri neuropati pada pasien DM tipe 2.Metode: Penelusuran dengan menggunakan basis data seperti google scholar, Pubmed dan Proquest dengan kriteria inklusi yang berfokus pada manajemen nyeri neuropati pada pasien DM, tahun publikasi antara 2010-2020 dalam bahasa Indonesia dan bahasa inggris, desain quasi experiment dan Randomized controlled trial. Didapatkan sebanyak 87 artikel, 32 memenuhi kriteria tahun dan sebanyak 19 merupakan artikel lengkap terakhir ditemukan sebanyak 10 artikel yang sesui fokus pencarian.Hasil: Intervensi manajemen neuropati dikelompokan menjadi exercise, teknik distraksi relaksasi, stimulasi listrik perkutan dan suportif edukatif.Simpulan: Exercise, tekhnik distraksi relaksasi, stimulasi listrik perkutan dan intervensi suportif edukatif menjadi salah satu intervensi yang dapat dipertimbangkan untuk digunakan pada manajemen nyeri neuropati pada pasien diabetes mellitus tipe 2 demi meningkatkan kenyamanan dan kualitas hidup.
3
Di Stefano, Giulia, Andrea Di Lionardo, Giuseppe Di Pietro, and Andrea Truini. "Neuropathic Pain Related to Peripheral Neuropathies According to the IASP Grading System Criteria." Brain Sciences 11, no. 1 (December 22, 2020): 1. http://dx.doi.org/10.3390/brainsci11010001.
Full textAbstract:
Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory system. Neuropathic pain represents a broad category of pain conditions, common complications of peripheral neuropathies, which are characterized by a combination of positive symptoms, including paresthesia and/or dysesthesia and sensory deficits in the painful area. In the present paper, we aimed to assess neuropathic pain frequency and clinical characteristics of peripheral neuropathies due to different aetiologies according to grading system criteria of the International Association for the Study of Pain for a definitive diagnosis of neuropathic pain. Epidemiological studies applying these criteria have been conducted in patients with diabetes, brachial plexus injury, and other traumatic nerve injuries. Neuropathic pain was diagnosed in 37–42% of patients with diabetic peripheral neuropathy, 56% of patients with brachial plexus injury, and 22% of patients with intercostobrachial neuropathy. The most frequent neuropathic pain type was ongoing pain (described as burning or pressing), followed by paroxysmal pain (electric shock-like sensations) and allodynia (pain evoked by brushing and pressure). By providing information on the frequency, clinical signs, and variables associated with neuropathic pain due to different aetiologies, these studies contribute to improving the clinical management of this condition.
4
Kluša, Vija, Juris Rumaks, and Ñina Karajeva. "Neuromidin Attenuates Neuropathic Pain in the Streptozocin-Induced Diabetes Model in Rats." Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 62, no. 3 (January 1, 2008): 85–90. http://dx.doi.org/10.2478/v10046-008-0024-z.
Full textAbstract:
Neuromidin Attenuates Neuropathic Pain in the Streptozocin-Induced Diabetes Model in Rats Diabetic neuropathy, which affects all peripheral nerves and may cause dramatic pain, is one of the most severe pathologies associated with hyperglycaemia, damage in the blood vessels, and inflammation in nerves. Anticonvulsants and antidepressants are still the most commonly used options to manage diabetic neuropathy. However, to improve clinical benefit in the treatment of diabetic neuropathies, as well as to minimize side effects, search for a new type of drugs to protect/treat neuropathic pain is still important. The aim of this study was to investigate neuromidin (ipidacrine, amiridin, NIK-247), an anticholinesterase drug of tetrahydroaminoacridine series, in the streptozocin (STZ)-induced diabetic neuropathic pain model in rats. Neuromidin was administered per os at daily doses 0.3, 1.0 and 3.0 mg/kg for ten days. The dynamics in the development of hyperalgesia (pain threshold) was measured by algesimeter for five weeks. The data obtained show that neuromidin considerably protects the development of peripheral neuropathic pain caused by STZ. The most active dose was the lowest—0.3 mg/kg. Neuromidin did not affect STZ-hyperglycemia, nor the weight gain in animal groups. Neuromidin per se at the doses 0.3 and 1.0 mg/kg showed a short-term analgesic activity. The cholinergic mechanism of neuromidin may be considered as essential in attenuating of diabetic neuropathic pain; other mechanisms remain to be elucidated.
5
Mokhtar, Nazarine, Stephane Doly, and Christine Courteix. "Diabetic Neuropathic Pain and Serotonin: What Is New in the Last 15 Years?" Biomedicines 11, no. 7 (July 6, 2023): 1924. http://dx.doi.org/10.3390/biomedicines11071924.
Full textAbstract:
The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) is involved in numerous physiological functions and plays a key role in pain modulation including neuropathic pain. Diabetic neuropathy is a common complication of diabetes mellitus often accompanied by chronic neuropathic pain. Animal models of diabetes offer relevant tools for studying the pathophysiological mechanisms and pharmacological sensitivity of diabetic neuropathic pain and for identifying new therapeutic targets. In this review, we report data from preclinical work published over the last 15 years on the analgesic activity of drugs acting on the serotonergic system, such as serotonin and noradrenaline reuptake inhibitor (SNRI) antidepressants, and on the involvement of certain serotonin receptors-in particular 5-HT1A, 5-HT2A/2c and 5-HT6 receptors-in rodent models of painful diabetic neuropathy.
6
Li, Hao, Shulin Liu, Zheng Wang, Yonglai Zhang, and Kaiguo Wang. "Hydrogen sulfide attenuates diabetic neuropathic pain through NO/cGMP/PKG pathway and μ-opioid receptor." Experimental Biology and Medicine 245, no. 9 (April 8, 2020): 823–34. http://dx.doi.org/10.1177/1535370220918193.
Full textAbstract:
Diabetic neuropathic pain is a frequent complication of diabetic neuropathy. The specific manifestations of diabetic neuropathic pain include spontaneous pain and hyperalgesia, which seriously affect the quality of life of patients. Previous publications have shown that H2S has both pro-nociceptive and anti-nociceptive effects. This present investigation aimed to examine the anti-nociceptive effect of H2S on diabetic neuropathic pain. We established a diabetic neuropathic pain animal model with high-glucose, high-fat diet, and STZ, then treated rats with different concentrations of H2S and inhibitors of NOS, sGC, PKG, and opioid receptors. The mechanical allodynia and thermal hyperalgesia of rats were measured to assess the anti-nociceptive effects of H2S. The mRNA and protein expression of NOS and PKG1 were measured to explore their roles in the anti-nociceptive action of H2S. The results revealed that inhalation of H2S gas had anti-nociceptive effect in diabetic neuropathic pain model rats without affecting the blood glucose level and body mass. It increased the mRNA and protein level of nNOS, and the inhibitor of nNOS, 7-NI, abolished the anti-nociceptive effect of H2S. Furthermore, inhibitors of sGC and PKG could also abolish the anti-nociceptive effect of H2S. The expression of PKG1 was found to be increased by H2S, which was reversed by the inhibitors of nNOS, sGC, and PKG. Finally, CTOP, a μ-opioid receptor antagonist, abolished the anti-nociceptive effect of H2S, indicating that the μ-opioid receptor plays a role in the anti-nociceptive effect of H2S. In conclusion, the findings of this investigation suggest that hydrogen sulfide may attenuate the diabetic neuropathic pain through NO/cGMP/PKG pathway and μ-opioid receptor. Impact statement There are currently approximately 425 million diabetic patients worldwide, of which approximately 90% of patients with diabetes suffer from neuropathy. Diabetic neuropathic pain (DNP) is a common complication of diabetic neuropathy. Nearly half of the patients hospitalized with diabetes have pain symptoms or symptoms related to neurological injury, and the incidence increases with age and diabetic duration. Anti-DNP analgesics have either limited therapeutic effects or serious side effects or lack of clinical trials, which has limited their application. Physiopathological mechanisms and treatment of DNP remain a significant challenge. The present confirmed that inhalation of H2S may attenuate the diabetic neuropathic pain through NO/cGMP/PKG pathway and μ-opioid receptor. It provides us the animal study foundation for the application of H2S on the treatment of DNP and clarifies some target molecules in the pain modulation of DNP.
7
Shabbir, Syed H. "Psychiatric Underpinnings of Chronic Diabetic Neuropathic Pain." Einstein Journal of Biology and Medicine 30, no. 1&2 (March 2, 2016): 37. http://dx.doi.org/10.23861/ejbm201530639.
Full textAbstract:
There is increasing evidence that psychosocial factors may be involved in the pathophysiology of chronic diabetic neuropathic pain. Individuals with diabetic polyneuropathy exhibit significantly higher rates of axis I psychiatric disorders, and worsening neuropathic symptoms correlate with worsened psychiatric illness. This association exists even when social-support and quality-of-life measures are controlled. Aberrant supraspinal structures and neuronal networks in diabetic neuropathy mimic those found in other psychiatric illnesses. Response to standard medications and therapeutic approaches remains unsatisfactory, and antidepressants continue to serve as first-line treatment for diabetic neuropathy. The exact interplay between neuropathic pain and psychiatric illness remains unclear and may have a common pathophysiological focus. This area of study needs to be revisited and psychological interventions must be explored as possible treatment options for diabetic neuropathy.
8
Zakin, Elina, Rory Abrams, and David M. Simpson. "Diabetic Neuropathy." Seminars in Neurology 39, no. 05 (October 2019): 560–69. http://dx.doi.org/10.1055/s-0039-1688978.
Full textAbstract:
AbstractDiabetes mellitus is becoming increasingly common worldwide. As this occurs, there will be an increase in the prevalence of known comorbidities from this disorder of glucose metabolism. One of the most disabling adverse comorbidities is diabetic neuropathy. The most common neuropathic manifestation is distal symmetric polyneuropathy, which can lead to sensory disturbances, including diminished protective sense, making patients prone to foot injuries. However, focal, multifocal, and autonomic neuropathies are also common. Diabetic nerve pain and Charcot osteoarthropathy are advanced neuropathic conditions that portend a severe deterioration in quality of life. To combat these symptoms, along with glycemic control and establishment of health care systems to educate and support patients with the complexities of diabetes, there are pharmacologic remedies to ameliorate the neurologic symptoms. Several guidelines and review boards generally recommend the use of tricyclic antidepressants, serotonin/norepinephrine-reuptake inhibitors, α-2-delta ligands, and anticonvulsants as medications to improve painful diabetic neuropathy and quality of life.
9
Schifilliti, Chiara, Lelio Cucinotta, Viviana Fedele, Carmela Ingegnosi, Salvatore Luca, and Carmelo Leotta. "Micronized Palmitoylethanolamide Reduces the Symptoms of Neuropathic Pain in Diabetic Patients." Pain Research and Treatment 2014 (April 2, 2014): 1–5. http://dx.doi.org/10.1155/2014/849623.
Full textAbstract:
The present study evaluated the effectiveness of micronized palmitoylethanolamide (PEA-m) treatment in reducing the painful symptoms experienced by diabetic patients with peripheral neuropathy. PEA-m, a fatty acid amide of the N-acylethanolamine family, was administered (300 mg twice daily) to 30 diabetic patients suffering from painful diabetic neuropathy. Before treatment start, after 30 and 60 days the following parameters were assessed: painful symptoms of diabetic peripheral neuropathy using the Michigan Neuropathy Screening instrument; intensity of symptoms characteristic of diabetic neuropathic pain by the Total Symptom Score; and intensity of different subcategories of neuropathic pain by the Neuropathic Pain Symptoms Inventory. Hematological and blood chemistry tests to evaluate metabolic control and safety were also performed. Statistical analysis (ANOVA) indicated a highly significant reduction in pain severity (P<0.0001) and related symptoms (P<0.0001) evaluated by Michigan Neuropathy Screening instrument, Total Symptom Score, and Neuropathic Pain Symptoms Inventory. Hematological and urine analyses did not reveal any alterations associated with PEA-m treatment, and no serious adverse events were reported. These results suggest that PEA-m could be considered as a promising and well-tolerated new treatment for symptomatology experienced by diabetic patients suffering from peripheral neuropathy.
10
Ekinci, Bilge, Bahadir Suleyman, Renad Mammadov, Arzu Gezer, Ali Mendil, Nergis Akbas, Seval Bulut, Cagatay Dal, and Halis Suleyman. "The effect of carvacrol upon experımentally ınduced dıabetıc neuropathy and neuropathıc paın ın rats." Acta Poloniae Pharmaceutica - Drug Research 79, no. 5 (January 20, 2023): 707–15. http://dx.doi.org/10.32383/appdr/155354.
Full textAbstract:
Diabetic neuropathies are the most frequent complication of diabetes. While numerous metabolic pathways are disrupted in diabetic neuropathy, oxidative stress has been indicated as a significant reason for this condition. In this study, the effect of carvacrol, which has antioxidant effects, on experimental diabetic neuropathy and neuropathic pain was investigated. Alloxan was used to induce diabetes in the experiment. Diabetes was created by administering 120mg/kg of alloxan intraperitoneally (i.p) once a day for 3 days. Rats with a blood glucose concentration above 250mg/kg in the blood taken from the tail veins at the end of three days were considered diabetic. Rats were categorized under healthy control (HG), alloxan-induced hyperglycemia (AG), and alloxan-induced hyperglycemia + carvacrol-treated (ACG) groups. Carvacrol was i.p injected at 50 mg/kg dose to the ACG (n=6) group of rats with hyperglycemia. The same volume of distilled water as the solvent was applied in the same way to AG (n=6) and HG (n=6) rat groups. This procedure was repeated once a day for three months.Carvacrol showed anti-hyperglycemic effect in diabetic rats, protective effect against lowering pain threshold and analgesic activity in rat paws in rats. Carvacrol prevented the oxidant/antioxidant balance from changing in favor of oxidants. The results supported that carvacrol is an agent against alloxan-induced peripheral diabetic neuropathic pain.
Dissertations / Theses on the topic "DIABETIC NEUROPATHIC PAIN"
1
Murai, Nobuhito. "Studies on the analgesic effect of (+)-indeloxazine on neuropathic pain." Kyoto University, 2014. http://hdl.handle.net/2433/193548.
Full text
2
CAZZATO, Daniele. "Clinical and genetic characterization of neuropathic pain through the model of small fiber neuropathy: implication for diabetic neuropathy." Doctoral thesis, Università degli studi di Ferrara, 2020. http://hdl.handle.net/11392/2478814.
Full textAbstract:
Il dolore neuropatico è una caratteristica frequente delle neuropatie periferiche, in particolare quando sono coinvolte le piccole fibre nervose che veicolano la sensibilità termo-dolorifica. La neuropatia delle piccole fibre (SFN) tipicamente si presenta con dolore urente distale agli arti e rappresenta un buon modello per lo studio del dolore neuropatico. Mutazioni nei geni dei canali del sodio voltaggio dipendenti (VGSC) sono state descritte in sindromi algiche familiari e nell’insensibilità congenita al dolore. Più recentemente, varianti in questi geni sono state identificate in associazione a condizioni più comuni quali le neuropatie dolorose. Obiettivo di questa tesi è di indagare il rischio di dolore neuropatico in una coorte ben caratterizzata di pazienti affetti da SFN e neuropatia diabetica. Nella prima sezione sono stati indagati gli aspetti clinici mediante una dettagliata caratterizzazione fenotipica dei pazienti con sospetto di SFN e dolore neuropatico, attraverso la progettazione di un database per la raccolta sistematica dei dati, l'integrazione e la condivisione tra medici e ricercatori. Tali dati sono stati utilizzati per condurre due studi retrospettivi. Il primo ha valutato l'accuratezza diagnostica della biopsia cutanea nel tempo, confrontando i diversi valori normativi per la densità di innervazione intraepidermica adottati dal 1999 al 2019. I risultati su 439 pazienti hanno evidenziato un significativo miglioramento della specificità diagnostica della biopsia cutanea dopo l'introduzione dei valori normativi corretti per età e sesso nel 2010, con una riduzione dei falsi positivi di oltre il 50%. Il secondo studio ha indagato le variazioni circadiane dell'intensità del dolore neuropatico in una coorte di 253 pazienti con sospetta SFN dolorosa rivelando un significativo incremento dell’intensità del dolore dal mattino/pomeriggio alla sera. Lo studio ha mostrato un pattern circadiano del dolore neuropatico che potrebbe fornire una misura di outcome aggiuntiva negli studi clinici per il trattamento del dolore neuropatico nella SFN. La seconda sezione include due studi finalizzati ad identificare determinanti genetiche associate a diversi fenotipi clinici in relazione all’eziologia e alla presenza o assenza di dolore neuropatico. Una prima analisi è stata effettuata su geni candidati, ricercando varianti rare e a bassa frequenza nei geni VGSC potenzialmente esercitanti maggiore effetto sul fenotipo clinico. L'analisi condotta su 1.015 pazienti ha mostrato una maggiore frequenza di varianti rare nei geni VGSC in pazienti con dolore rispetto al fenotipo senza dolore (13,5% e 9,7%) ma nessuna differenza significativa dividendo il campione sulla base dell’eziologia diabetica o idiopatica (11,5%). Osservando la distribuzione delle varianti nei geni VGSCs, i pazienti idiopatici e quelli con dolore presentavano una frequenza significativamente più alta di varianti in SCN9A, mentre nei pazienti con diabete e in quelli senza dolore prevalevano varianti nel gene SCN10A. Tuttavia, la maggior parte di queste varianti sono state classificate come VUS (varianti di significato sconosciuto), pertanto esistono dubbi circa il loro reale significato patogenetico. Sulla base dell'ipotesi di un'architettura poligenica della neuropatia dolorosa in cui tutte le varianti, sia rare che comuni, possono contribuire al fenotipo clinico, è stato adottato un nuovo approccio per indagare il rischio di dolore neuropatico nei pazienti con diabete. E’ stato calcolato un punteggio di rischio poligenico (PRS) combinando il peso di ogni variante identificata in un pannello di 107 geni correlati al dolore, in pazienti affetti da neuropatia diabetica con e senza dolore. Il PRS è stato in grado di discriminare con una sufficiente accuratezza pazienti con dolore da quelli senza dolore. Questo studio rappresenta la prima applicazione del PRS nello studio del dolore neuropatico associato a neuropatia diabetica.Neuropathic pain is a frequent feature in peripheral neuropathy in particular when small nerve fibers, which convey thermal and nociceptive sensations, are involved. Excruciating burning pain at feet and hand is the most common feature of small fiber neuropathy (SFN) which represents a good model for studying neuropathic pain. Voltage gated sodium channel (VGSCs) genes mutations have been found in rare familial painful disorders and more recently, variants in the same genes have been identified in idiopathic and diabetic painful neuropathies, thus widening the spectrum of genetic pain disorders. This PhD thesis aimed at investigating the risk for neuropathic pain in a well-phenotyped cohort of SFN and diabetic neuropathy patients in order to provide a clinical and genetic characterization of patients. The first section focused on the deep-phenotyping of patients with suspected SFN or neuropathic pain through the development of a database for systematic data collection, integration and sharing among clinicians and researchers. Collected data have been used to conduct two retrospective studies. The first study aimed at addressing the diagnostic accuracy of skin biopsy over time comparing the different normative values for intraepidermal nerve fiber density (IENFD) adopted from 1999 to 2019. This study, comparing skin biopsy results in 439 patients according to different cut-off values, showed a significant improvement of skin biopsy diagnostic specificity after the introduction of the age-and-sex-adjusted normative reference values in the 2010, reporting a reduction of false positive of more than 50% when compared with the cut-off values previously adopted. The second study investigated the circadian dynamics of neuropathic pain intensity scored using the numeric rating scale (PI-NRS) in a cohort of 253 patients with suspected painful SFN. This study revealed a circadian pattern of pain features, showing an increase of NRS scores towards the evening, suggesting a possible role for the intra-day PI-NRS variations as adjunctive outcome measure in clinical trials for analgesic drug in SFN-related neuropathic pain. The second section of the thesis provided a genetic characterization of SFN patients. A candidate-gene analysis has been conducted, looking for rare and low frequency genetic variants in VGSCs genes expected to have a large effect on clinical phenotype and describing their frequency in phenotypically well-defined cohorts of SFN patients. The analysis conducted on 1,015 patients grouped according to etiology and painful phenotype showed a slightly higher frequency of VGSCs variants in painful compared to painless phenotype (13.5% and 9.7%, respectively) but no significant differences between diabetes and idiopathic SFN patients (11.5%). Looking at the variants distribution in VGSCs genes, idiopathic and painful patients showed a significant higher frequency of SCN9A variants whereas diabetes and painless patients had more variants in SCN10A gene. However, concerns have been raised about the pathogenicity of single rare gain-of-function variants, since most of them were classified as VUS (variants of unknown significance). Based on these findings, we adopted a new research approach to investigate the risk of neuropathic pain in our diabetic cohort of 513 patients. The work hypothesis relied on a polygenic architecture of painful neuropathy in which all variants, whether rare or common, might contribute with a small effect size to compose the clinical phenotype. Therefore, we computed a polygenic risk score (PRS) combining the weight of each variant identified in a panel of 107 pain-related genes in diabetic neuropathy patients. The PRS was able to discriminate with sufficient accuracy painful from painless patients with an AUC of 60.3%. This study represented the first application of PRS for addressing the risk of neuropathic pain in diabetic neuropathy, pioneering the use of this tool in this clinical context.
3
Humble, Stephen R. "Neurosteroids : endogenous analgesics?" Thesis, University of Dundee, 2013. https://discovery.dundee.ac.uk/en/studentTheses/c4659466-cd41-494d-aec6-edcf50e5274b.
Full textAbstract:
Peripheral sensitisation and central sensitisation are implicated in the development of neuropathic pain with neuroplasticity occurring at multiple levels of the pain pathway. Hypersensitivity of the spinothalamic tract has been described in neuropathic animal models of diabetes. Spinal dorsal horn neurones of diabetic rats exhibit abnormally high spontaneous firing, suggesting an imbalance between excitatory and inhibitory signals converging within this structure. GABAergic neurones within the spinal cord and thalamus are crucial for the transmission of painful stimuli to higher centres of the brain that are involved in pain perception. GABAA receptors (GABAARs) are an important target for many clinical drugs, and certain endogenous neurosteroids act as potent allosteric modulators of these receptors. A developmental change in the rate of exponential decay of GABAergic synaptic events has been observed in other types of neurones and this may be related in part to fluctuations in endogenous neurosteroid tone. The objective of this study was to investigate changes to inhibitory neurotransmission with development in three levels of the pain pathway and to explore potential mechanisms underlying diabetic neuropathy. The whole-cell patch-clamp technique was used on slices of neural tissue. Electrophysiological recordings were obtained from wild type mice between the ages of 6 and 80 days in lamina II of the spinal cord, the nucleus reticularis (nRT) of the thalamus and the cerebral cortex. Recordings were also obtained from mice with diabetic neuropathy (ob/ob and db/db) between the ages of 60 and 80 days. Neurosteroids and their precursors were employed along with compounds that prevented their activity at the GABAAR such as ?-cyclodextrin, which is a barrel-shaped cyclic oligosaccharide with a lipophilic interior that sequesters neurosteroids. Behavioural experiments were also performed using von Frey filaments and the tail flick test to examine mechanical and thermal nociception. Recordings from the spinal cord, the thalamus and the cerebral cortex revealed that the decay time of miniature inhibitory postsynaptic currents are significantly reduced with development. The neurosteroids allopregnanolone and ganaxolone were significantly more effective in neurones from the older mice. In contrast, ?-cyclodextrin had significantly less effect in neurones from the older mice. In mature diabetic mice (ob/ob mice), the endogenous neurosteroid tone is reduced compared to control mice, but certain neurosteroid compounds have a greater effect on the GABAARs of these diabetic mice. In addition, the diabetic mice exhibit mechanical allodynia and hyperalgesia, which is responsive to exogenously applied neurosteroids. These results are consistent with the hypothesis that a dramatic reduction in endogenous neurosteroid tone occurs as development progresses and that this impacts on the exponential decay time of GABAergic mIPSCs within neurones of the pain pathway. The higher neurosteroid tone in the youngest mice may confer a degree of neural protection over the nervous system as it develops. The reduction of endogenous neurosteroid tone in diabetic mice may be associated with their hypersensitivity. It is possible that pregnane-derived neurosteroids may exert analgesic effects in pathological pain states by attempting to restore the physiological GABAergic inhibitory tone that is observed in immature animals.
4
Evangelista, Afrânio Ferreira. "Avaliação do efeito do transplante de células-tronco mesenquimais derivadas de medula óssea em modelo murino de neuropatia periférica diabética." Centro de Pesquisas Gonçalo Moniz, 2014. https://www.arca.fiocruz.br/handle/icict/9646.
Full textAbstract:
Submitted by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2015-03-06T16:58:42Z
No. of bitstreams: 1
Afrânio Ferreira Evangelista Avaliação...2014.pdf: 2792913 bytes, checksum: 154973247ed482dbfeac342e4b641d7c (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2015-03-06T17:00:06Z (GMT) No. of bitstreams: 1 Afrânio Ferreira Evangelista Avaliação...2014.pdf: 2792913 bytes, checksum: 154973247ed482dbfeac342e4b641d7c (MD5)
Approved for entry into archive by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2015-03-06T17:01:18Z (GMT) No. of bitstreams: 1 Afrânio Ferreira Evangelista Avaliação...2014.pdf: 2792913 bytes, checksum: 154973247ed482dbfeac342e4b641d7c (MD5)
Made available in DSpace on 2015-03-06T17:01:18Z (GMT). No. of bitstreams: 1 Afrânio Ferreira Evangelista Avaliação...2014.pdf: 2792913 bytes, checksum: 154973247ed482dbfeac342e4b641d7c (MD5) Previous issue date: 2014
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
O diabetes é uma doença de alta prevalência que, frequentemente, induz o comprometimento do sistema nervoso periférico. Na neuropatia diabética periférica, os sintomas mais encontrados são os sensitivos, no qual a dor neuropática, condição crônica caracterizada por alodinia e hiperalgesia, é a mais debilitante. Esta, prejudica a qualidade de vida do paciente, sendo muitas vezes não responsiva aos métodos farmacológicos convencionais de tratamento. Diante desse panorama, o desenvolvimento de novas abordagens terapêuticas que possuam ação efetiva neste tipo de dor é de grande relevância. O uso da terapia celular no tratamento de lesões do sistema nervoso tem demonstrado resultados promissores e o potencial terapêutico de células-tronco na neuropatia experimental tem sido proposto. Neste estudo, avaliou-se o efeito de células-tronco mesenquimais derivadas da medula óssea (CMsMO) na neuropatia diabética periférica estabelecida em modelo experimental de diabetes induzido por estreptozotocina (ETZ). Quatro semanas após a indução do modelo por ETZ (80 mg/kg; ip; 3 dias consecutivos), os animais receberam uma administração endovenosa de CMsMO (1 x 106) ou veículo. O tratamento com gabapentina (30 mg/kg; v.o. a cada 12 horas durante seis dias consecutivos) foi usado como padrão ouro. Os limiares nociceptivos térmico e mecânico foram avaliados durante todo o período experimental (90 dias), pelos métodos de hargreaves e von Frey. A avaliação da função motora foi realizada pelo teste de rota-rod. Em diferentes tempos e para todos os grupos experimentais, foram realizadas coletas de segmentos da medula espinal (L4-L5) para dosagem de citocinas por ELISA e segmentos do nervo isquiático foram também coletados para avaliação de alterações morfológicas por microscopia óptica e eletrônica de transmissão. Os dados comportamentais demonstraram que o tratamento com CMsMO reduziu a mecanoalodinia e a hipoalgesia térmica, levando os limiares nociceptivos de animais neuropáticos a níveis similares aos de animais não neuropáticos. Do mesmo modo, a administração de CMsMO normalizou a função motora dos animais neuropáticos. Dados de microscopia mostraram que animais neuropáticos apresentaram atrofia axonal, redução do número de fibras mielínicas e aparente redução do numero de fibras amielínicas no nervo isquiático. Animais neuropáticos tratados com CMsMO tiveram menor ocorrência de atrofia axonal e não apresentaram redução do numero de fibras mielínicas ou amielínicas, em relação aos neuropáticos tratados com salina. Além disso, animais neuropáticos tratados com CMsMO apresentaram menores níveis espinais de IL-1β e TNF-α, e maiores de IL-10 e TGF-β, em relação aos animais neuropáticos não tratados. Esse conjunto de resultados indica que CMsMO produzem efeito antinociceptivo duradouro na neuropatia diabética, seguido de modificações no padrão fisiopatológico da doença, o que aponta a terapia celular como uma interessante alternativa para o controle da neuropatia diabética periférica dolorosa.
Diabetes is a highly prevalent disease which frequently compromises the peripheral nervous system. In peripheral diabetic neuropathy, the most frequent symptoms are sensitive, in which the neuropathic pain, chronic condition characterized by allodynia and hyperalgesia, is the most debilitating. Neuropathic pain affects the quality of patients’ lives, and is often not responsive to pharmacological conventional treatment methods. Against this background, the development of new therapeutic approaches that have an effective action in this type of pain is of great importance. The use of cell therapy in the treatment of lesions in the nervous system has shown promising results and the therapeutic potential of stem cells in experimental neuropathy has been proposed. In this study, we evaluated the effect of mesenchymal stem cells derived from bone marrow (CMsMO) in peripheral diabetic neuropathy established in experimental model of streptozotocin (STZ) induced diabetes in mice. Four weeks after the induction of the model by administration of STZ (80 mg/kg, ip; 3 days) the animals received an CMsMO by intravenous administration (1x106) or vehicle. The treatment with gabapentin (30 mg/kg, orally every 12 hours for six days) was used as the gold standard. The thermal and mechanical nociceptive thresholds were assessed throughout the entire experimental period (90 days), using Hargreaves and von Frey methods, respectively. Motor function evaluation of was conducted using the rotarod test. At different times, were analyzes conducted in spinal cord segments (L4-L5) to determine cytokines profile by ELISA. Sciatic nerve segments were also collected for evaluation of morphological changes by optical and electron transmission microscopy. According to the behavioral data, the CMsMO treatment reduced the mecanoalodinia and the thermal hypoalgesia, leading nociceptive thresholds of neuropathic animals to levels similar to those of non-neuropathic animals. Similarly, CMsMO administration normalized motor function of neuropathic animals. Microscopy data demonstrated that neuropathic animals had axonal atrophy and an apparent decrease of the number of myelinated fibers as well a reduction in the number of unmyelinated fibers in the sciatic nerve, but neuropathic animals treated with CMsMO had a lower incidence of axonal atrophy, showed no decrease in the number of myelinated fibers and no apparent decrease in the amount of unmyelinated fibers in relation to neuropathics treated with saline. Furthermore, neuropathic animals treated with CMsMO presented lower levels of spinal IL-1β and higher levels of TNF-α, and IL-10 and TGF-β compared to neuropathic animals that received saline. These data indicate that CMsMO produces a lasting analgesic effect in diabetic neuropathy, followed by changes in the pathophysiological disease pattern, which indicates cell therapy as an interesting alternative for the control of painful peripheral diabetic neuropathy.
5
Chan, A. W. "Neuropathic pain in diabetes mellitus." Thesis, Cardiff University, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.496046.
Full text
6
Kwiatkowska, Katarzyna Malgorzata <1987>. "Epigenetic Landscape of Pain in Diabetic Neuropathy." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2021. http://amsdottorato.unibo.it/9577/1/phdThesis_epicPainNet_KKwiatkowska_final.pdf.
Full textAbstract:
The available treatments for neuropathic pain are still unsatisfactory – they cope with low efficiency and serious side effects. To our knowledge, this is a pioneering study evaluating whole-genome DNA methylation in unique populations of type 2 diabetes mellitus patients that were histopalogically diagnosed with diabetic neuropathy, with or without neuropathic pain. We provided an evidence on the significant differences in methylation patterns between painful and painless phenotypes.
Epigenomes of patients from two independent cohorts were assessed in whole blood samples with Infinium Methylation EPIC BeadChip. We performed differential analysis and identified epigenetic signals that highlight the dissimilarities between painful and painless subjects. We estimated epigenetic age of the patients and evaluated eventual acceleration of biological age in painful and painless phenotypes using set of epigenetic predictors.
With the differential analysis we identified 27 CpG sites that reached the level of statistical significance in both studied cohorts, presented the methylation change between painful and painless diabetic neuropathy > 1% in one of the populations and had the direction of methylation change concordant between the two cohorts. 19 of selected probes were genic and resulted in a list of 19 unique genes. Multidimensional scaling analysis confirmed the potential of generated set of CpG sites to separate painful and painless subjects and to highlight the dissimilarities between two phenotypes.
Evaluation of biological age showed that there was no association between painful phenotype and acceleration of biological age expressed by any of the assessed epigenetic clocks. DNA methylation based prediction of telomere length was found to vary between painful and painless groups in both studied cohorts.
Obtained results confirmed the presence of epigenetic differences between painful and painless diabetic neuropathy patients. Promising genes were identified that may be linked to neuropathic pain through DNA methylation mechanisms.
7
George, Mary Catherine. "A Comparison of Neuropathic Pain in HIV Disease and Diabetes Mellitus." ScholarWorks, 2017. https://scholarworks.waldenu.edu/dissertations/3989.
Full textAbstract:
Neuropathy is a nerve disorder found in HIV disease and diabetes mellitus that indicates damage in the peripheral nervous system. Burning, tingling, stabbing, shooting, and painful sensations in the hands and feet are common symptoms of this chronic disorder, and no treatments are available that repair the nerves. The approved pain treatments are few and only available for the diabetic neuropathy population. A mixed-methods study of archival data was performed to compare patients with painful neuropathy (PN) associated with 2 diseases: HIV (HIV-PN) and diabetes mellitus (DPN). This study examined the similarities and differences of the pain narratives and common pain questionnaires from 12 HIV-PN and 11 DPN subjects. An independent t test of the Visual Analog Scale, Numeric Rating Scale, Brief Pain Intensity subscale, and the Short Form McGill Pain questionnaire failed to reject the null hypothesis that HIV-PN and DPN have equal pain levels. The qualitative analysis revealed 8 shared themes in both groups, with footwear challenges reported as the primary theme. This finding supports the many shared themes between these groups, yet education addressing these themes is minimal. One contrasting theme, privacy, was detected in the HIV-PN group, correlating statistically with the Beck Depression Inventory findings of guilt feelings. The theme of exercise was unique for the DPN group. Both groups had paralinguistic and nonverbal elements discovered in the recordings demonstrating the need for future research to explore these components. Results of education and research themes of privacy in the HIV-PN group and pain communication strategies for both groups will increase understanding of etiology, intervention, and patterns of pain for those diagnosed with neuropathy.
8
Toniolo, Elaine Flamia. "Caracterização da hemopressina (agonista inverso de receptores canabinóides do tipo 1) na neuropatia diabética experimental." Universidade de São Paulo, 2015. http://www.teses.usp.br/teses/disponiveis/42/42136/tde-09122015-064117/.
Full textAbstract:
A neuropatia periférica diabética é caracterizada por hiperalgesia e alodínia. O receptor CB1 é o principal responsável pelo efeito dos canabinóides na via nociceptiva. A Hemopressina (Hp), é um agonista inverso do CB1, que induz antinocicepção. Neste trabalho investigamos o efeito do tratamento com Hp (2,5 mg/Kg, por 28 dias) sobre a neuropatia diabética de camundongos, induzido por estreptozotocina (200mg/kg). A Hp reverte a hipersensibilidade mecânica em camundongos com neuropatia diabética, sendo que este efeito é específico para o tratamento da nocicepção e envolve a participação de receptores CB1, astrócitos e microglia em nível espinal. A Hp também previne a desmielinização do nervo isquiático dos animais diabéticos, e auxilia na manutenção dos níveis do NGF. Ainda, a Hp participa no controle da sensibilidade ao estímulo térmico quente em animais KO MOR e participa do controle da sensibilidade mecânica de animais KO MOR diabéticos pelo aumento da dimerização de CB1-DOR na medula espinal. Revelando a Hp um candidato para fins terapêuticos.Diabetic peripheral neuropathy is characterized by hyperalgesia and allodynia. CB1 receptors are primarily responsible for the effect of cannabinoids in nociceptive pathways. Hemopressin (Hp) is an inverse agonist of CB1, which induces antinociception. In this study we investigated the effects of treatment with Hp (2.5 mg / kg for 28 days) on mice subjected to diabetic neuropathy by streptozotocin (STZ - 200 mg/kg). Hp treatement reversed the mechanical hypersensitivity in mice with neuropathy diabetic, and this effect is specific for the treatment of nociception and involves the participation of CB1 receptors, astrocytes and microglia at the spinal level. Hp prevented demyelination of the sciatic nerve in diabetic animals, and assisted in mantaining the levels of NGF. Also, Hp participates in the control of heat sensitivity to thermal stimulus in KO MOR animals and participates in the control of mechanical sensitivity in KO MOR diabetics animals by the increase in CB1-DOR dimerization in the spinal cord. Revealing Hp as a candidate for therapeutic purposes.
9
DONVITO, GIULIA. "PHARMACOLOGICAL EFFECTS OF PALMITOYLETHANOLAMIDE (PEA) IN DIFFERENT ANIMAL MODELS OF NEUROPATHIC PAIN." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2016. http://hdl.handle.net/10281/101790.
Full textAbstract:
Neuropathic pain is defined by the International Association for the Study of Pain (IASP) as pain that arises as a direct consequence of a lesion or disease affecting the somatosensory system.
Neuropathic pain is often poorly alleviated by first-, and second-line medications recommended by IASP due to lack of efficacy and/or dose-limiting side-effects. Hence, there is an urgent need to develop novel mechanism-based therapeutic agents that are highly efficacious and well tolerated to improve relief of neuropathic pain. Palmitoylethanolamide (PEA) is the parent molecule of ALIAmides (Autacoid Local Injury Antagonism Amides), a group of endogenous fatty acid derivatives sharing anti-inflammatory and antinociceptive effects with the endocannabinoid family mainly through the down-modulation of local mast cell degranulation. Several evidences in literature show the antinociceptive effect of PEA in different animal models of pain, such as spinal cord injury, chronic constriction injury of the sciatic nerve, carrageenan-induced acute inflammation, and complete Freund’s adjuvant-induced chronic inflammation. Based on these fundings, the aim of this study is to further explore the therapeutic potentiality of PEA in resolving painful states in three very common forms of neuropathic pain in human associated to osteoarthritis, diabetes, and chemotherapy.
Osteoarthritis (OA) is the most common chronic joint disease characterized by a progressive destruction of cartilage, resulting in pain, and loss of articular function. The monosodium iodoacetate (MIA) rat model of OA was used to investigate the effects of PEA. Under a chronic
treatment regiment, PEA was able to completely abolish knee swelling and thermal hyperalgesia, as index of inflammation. Moreover, treatment with PEA resulted in a significant relief of mechanical allodynia, as index of neuropathic pain. Futhermore, PEA treatment completely restored locomotor functionality, and is also able to preserve cartilage from damage.
Diabetes mellitus is a metabolic syndrome today affecting 382 million people. One of the most disabling long-term complications of diabetes is diabetic neuropathy. The well established streptozotocin (STZ)-induced mice model of type 1 diabetes was emploied to explore the
antinociceptive effect of PEA in diabetic neurophaty. PEA relieved mechanical allodynia, counteracted nerve growth factor deficit, improved insulin level, preserved Langherans islet morphology reducing the development of insulitis in diabetic mice.
Chemotherapy-induced neuropathic pain (CINP) is another common form of neurophatic pain,
affecting up to 90% of patients. The effect of PEA in paclitaxel model of CINP, one of the most common used antineoplastic drugs in clinic, was investigated. Preliminary results show that PEA is able to evoke a total antiallodynic effect in CINP model, after acute administration.
The results of this thesis show the pharmacological effect of PEA to relieve neuropathic pain associated to osteoarthritis, diabetes, and chemotherapy, three very common diseases in human, that lack a resolutive, and effective treatment. These findings allow us to suggest a therapeutic use of PEA in clinic.
10
Potter, Jeannette Dawn Francesca. "The natural history of neuropathic pain amongst patients with diabetes and patients with cancer." Thesis, King's College London (University of London), 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.415558.
Full textBooks on the topic "DIABETIC NEUROPATHIC PAIN"
1
Boulton, Andrew J. M., and Loretta Vileikyte. Managing Neuropathic Pain in the Diabetic Patient. Tarporley: Springer Healthcare Ltd., 2009. http://dx.doi.org/10.1007/978-1-908517-16-6.
Full text
2
Galer, Bradley S. Defeat chronic pain now: Groundbreaking strategies for eliminating the pain of arthritis, back and neck conditions, migraines, diabetic neuropathy, and chronic illness. Beverly, MA: Fair Winds Press, 2010.
Find full text
3
Galer, Bradley S. Defeat chronic pain now!: Groundbreaking strategies for eliminating the pain of arthritis, back and neck conditions, migraines, diabetic neuropathy, and chronic illness. Beverly, MA: Fair Winds Press, 2010.
Find full text
4
Galer, Bradley S. Defeat chronic pain now: Groundbreaking strategies for eliminating the pain of arthritis, back and neck conditions, migraines, diabetic neuropathy, and chronic illness. Beverly, MA: Fair Winds Press, 2010.
Find full text
5
Nageshwaran, Sathiji, Heather C. Wilson, Anthony Dickenson, and David Ledingham. Neuropathic pain. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199664368.003.0005.
Full textAbstract:
This chapter on neuropathic pain discusses the classification, clinical features, and evidence-based management of major neuropathic pain syndromes (painful polyneuropathy, diabetic neuropathy, post-herpetic neuralgia, HIV neuropathy, cancer neuropathic pain, phantom pain, traumatic neuropathic pain, chronic radiculopathy, central neuropathic pain, and trigeminal neuralgia).
6
Khursheed, Faraz, and Marc O. Maybauer. Neuropathic Pain. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190271787.003.0012.
Full textAbstract:
Neuropathic pain is a common condition that arises from injury anywhere along the somatosensory axis. Although the presentation may vary based on mechanisms and locations of injury, most patients have characteristic burning, shocklike, lancinating pain, most often in the distribution of peripheral and spinal nerves or distal extremities. Various peripheral and central processes aggravate pain through abnormal impulse generation, modulation, and processing. Common conditions include complex regional pain syndrome, diabetic neuropathy, postherpetic neuralgia, spondylotic radiculopathy, and central pain syndromes. A detailed history and physical examination will aid in differentiating various neuropathic pain conditions. Neuropathic pain is best managed using a true multidisciplinary approach.
7
Boulton, Andrew Jm, and Loretta Vileikyte. Managing Neuropathic Pain in the Diabetic Patient. Springer, 2012.
Find full text
8
Vileikyte, Loretta, and Andrew JM Boulton. Managing Neuropathic Pain in the Diabetic Patient. Springer Healthcare, 2011.
Find full text
9
Shaibani, Aziz. Numbness. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190661304.003.0023.
Full textAbstract:
Sensory symptoms are the most common symptoms in neuromuscular clinics, yet it is hard to capture them via video unless they have a very specific pattern and they are associated with objective loss of sensation. Distal sensory loss is a common neuropathic finding. It follows gloves and stocks distribution. Sensory neuropathies may present with ataxia which results in falls, or severe pain. Neuropathic pain with normal ankle reflexes and sural responses suggest small fiber neuropathy. Multifocal sensory loss is usually vascular. It can also be infectious (leprosy). Migratory neuritis is a poorly understood condition. Intercostal pain and numbness is usually due to radiculopathy (diabetic, zoster, or compressive radiculopathy). Foots ulcers and unfelt mosquito bites are markers for sensory loss. Loss of corneal sensation may led to keratitis and blindness.
10
Shaibani, Aziz. Numbness. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199898152.003.0023.
Full textAbstract:
Sensory symptoms are the most common symptoms in neuromuscular clinics, yet it is difficult to capture them in videos unless they have a very specific pattern and/or they are associated with objective loss of sensation. Distal sensory loss is a common neuropathic finding. Sensory neuropathies may also present with ataxia or severe pain. Multifocal sensory loss is usually vascular (vasculitis, diabetic amyotrophy). Intercostal pain and numbness are due to radiculopathy (diabetic, zoster, or compressive radiculopathy). Thoracic and abdominal radiculopathies are often misdiagnoses as acute coronary or abdominal emergencies respectively. The distribution of pain and the associated tingling and skin sensitivity to touch are important clues to their neuropathic nature.
Book chapters on the topic "DIABETIC NEUROPATHIC PAIN"
1
Calcutt, Nigel A., and Sandra Chaplan. "Neuropathic Pain Model, Diabetic Neuropathy Model." In Encyclopedia of Pain, 2075–79. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-28753-4_2679.
Full text
2
Tran, Hai, and Daryl I. Smith. "Diabetic Peripheral Neuropathy." In Pathogenesis of Neuropathic Pain, 143–53. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-91455-4_8.
Full text
3
Boulton, Andrew J. M., and Loretta Vileikyte. "Management of Neuropathic Pain." In Painful Diabetic Neuropathy in Clinical Practice, 41–58. London: Springer London, 2011. http://dx.doi.org/10.1007/978-0-85729-488-3_4.
Full text
4
Sawada, Atsushi, and Michiaki Yamakage. "Neuropathic Pain Syndrome: Diabetic and Other Neuropathies." In Chronic Pain Management in General and Hospital Practice, 249–60. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-2933-7_14.
Full text
5
Boulton, Andrew J. M., and Loretta Vileikyte. "Management of neuropathic pain." In Managing Neuropathic Pain in the Diabetic Patient, 35–48. Tarporley: Springer Healthcare Ltd., 2011. http://dx.doi.org/10.1007/978-1-908517-16-6_4.
Full text
6
Dobretsov, Maxim, Miroslav Misha Backonja, Dmitry Romanovsky, and Joseph R. Stimers. "Animal Models of Diabetic Neuropathic Pain." In Animal Models of Pain, 147–69. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-880-5_9.
Full text
7
Boulton, Andrew J. M., and Loretta Vileikyte. "Introduction to diabetic neuropathies." In Managing Neuropathic Pain in the Diabetic Patient, 1–5. Tarporley: Springer Healthcare Ltd., 2011. http://dx.doi.org/10.1007/978-1-908517-16-6_1.
Full text
8
Boulton, Andrew J. M., and Loretta Vileikyte. "Classification and clinical features." In Managing Neuropathic Pain in the Diabetic Patient, 7–19. Tarporley: Springer Healthcare Ltd., 2011. http://dx.doi.org/10.1007/978-1-908517-16-6_2.
Full text
9
Boulton, Andrew J. M., and Loretta Vileikyte. "Diagnosis and staging." In Managing Neuropathic Pain in the Diabetic Patient, 21–33. Tarporley: Springer Healthcare Ltd., 2011. http://dx.doi.org/10.1007/978-1-908517-16-6_3.
Full text
10
Gok Metin, Zehra. "Common Meanings of Living with Diabetic Peripheral Neuropathic Pain from the Perspective of Patients." In Meanings of Pain, 209–31. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-24154-4_11.
Full textConference papers on the topic "DIABETIC NEUROPATHIC PAIN"
1
Stella, Isabela de Almeida, Herval Ribeiro Soares Neto, Vanessa de Freiras Moreira, Arthur da Veiga Kalil Coelho, Kássia Braga Canzian, Marcella Canato Toloi, Amanda Freitas Alves, and Sephora Sabrina Candido. "Response of neuropathic pain to intravenous immunoglobulin in diabetic amyotrophy: a case report." In XIV Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2023. http://dx.doi.org/10.5327/1516-3180.141s1.686.
Full textAbstract:
Introduction: A 58-year-old male patient, diagnosed with diabetes mellitus (DM) five years ago, started with neuropathic pain in the lumbar region radiating to the right thigh, and later to the left thigh, progressing to difficulty walking and significant weight loss over six months. On examination, patient with grade IV proximal paraparesis, slightly asymmetrical, associated with muscle atrophy and abolished reflexes. Regarding the upper limbs, the examination was normal. During the investigation, electroneuromyography (ENMG) showed sensory and motor involvement in the lower limbs, with a mixed pattern, associated with cerebrospinal fluid with hyperproteinorrachia. The rest of the exams did not show alterations, raising the hypothesis of diabetic amyotrophy (DA). Discussion: DA affects less than 1% of all diabetic patients. Its typical clinical presentation is the presence of acute pain in the proximal region of the lower limbs, initially unilateral, evolving with paresis and muscle atrophy, as well as involvement of the contralateral limb in more advanced cases. The diagnosis is based mainly on clinical suspicion. ENMG demonstrates a pattern more related to axonal degeneration than demyelination, generally sparing upper limbs. Currently, there is no evidence to support or contraindicate any immunotherapy in the treatment of DA. In this case, IVIg was performed with excellent response in pain control. Conclusion: Despite being a less common complication related to DM, DA becomes important in a scenario of increased incidence of metabolic diseases in the Brazilian population. It is important to know its presentation to aid in the diagnosis of a disease thais is rate but with an excellent response to IVIg infusion.
2
Rizk, Carine, Koby Reid, Khue Tran, and Hannah Bass. "PREVENTING THE PROGRESSION OF DIABETIC FOOT ULCERS: ADDRESSING PATIENT COMPLIANCE WITH LOW-COST, BEHAVIOR-MODIFYING WEARABLES." In 2023 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2023. http://dx.doi.org/10.1115/dmd2023-7569.
Full textAbstract:
Abstract Over 34.2M Americans have diabetes and $237B is spent on direct costs of diabetes each year. Of this, $15B is spent on foot ulcer treatment alone as more than half of people with diabetes develop some type of neuropathy, the primary modifiable risk factor of ulcers in this population. Currently, patients with diabetic peripheral neuropathy (DPN) rely on early hotspot identification, padded soles, offloading boots, and diabetic shoes, with compliance being the major issue. Through expert interviews, there is a need for a better method to slow and prevent the progression of hot spots and other complications in patients with DPN. Our team is proposing DiaSense, a wearable device that replaces the lost sensation of pain with a safe and actionable stimulus that modifies gait to offload hotspots. The discrete design was guided by experiences from patients, podiatrists, and vascular surgeons to improve patient compliance, satisfaction, and recovery. Early user-feedback demonstrated useful validation that our device modifies walking behavior in healthy participants, and helps justify a larger study with patients who have diabetic peripheral neuropathy.
3
Petersen, Erika, Thomas Stauss, James Scowcroft, Michael Jaasma, Judith White, Shawn Sills, Kasra Amirdelfan, et al. "10 kHz SCS Provides Durable Pain Relief and Neurological Improvements for Patients with Painful Diabetic Neuropathy: 24-Month RCT Results (PL4.004)." In 2023 Annual Meeting Abstracts. Lippincott Williams & Wilkins, 2023. http://dx.doi.org/10.1212/wnl.0000000000202464.
Full text
4
Gulhote, Daniela Alves, Gabriel Santaterra Barros, Mariana Suemi Sukessada, Ana Beatriz Barbosa Piffer, João Fernando Coclet Pio da Silva, Pedro Neves Fortunato, Danilo Takashi Yoshimatsu Ueno, Bruna Franchito Freire, and Hilton Mariano da Silva Junior. "Painful ophthalmoplegia due to involvement of cavernous sinus region by malignant neoplasm: report of three cases." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.621.
Full textAbstract:
Context: Intracranial tumor spread is an infrequent and late manifestation of head and neck cancers. We report three cases of painful ophthalmoplegia due to larynx and parotid neoplastic involvement. Data disclosure was authorized by the patients through an Informed Consent Form. Case reports: A 47-year-old man presents right retro- orbital pain and progressive ophthalmoplegia 5 months after resection of laryngeal spinocellular carcinoma and local radiotherapy. A 44-year-old man, 9 months after excision of spinocellular carcinoma of the larynx and subsequent radiotherapy, presents severe pain and paralysis of the left CN VI. Imaging exams showed involvement of CS. A 67-year-old woman with a tumoral mass in the left preauricular region. Biopsy revealed adenocarcinoma of the parotid gland. After total parotidectomy, the supra-omohyoid cervical ganglion was removed. Patient received radiotherapy for 3 months. Then, she presented a frontal and right temporal headache, more intense in the retro-orbital region. After one month, she developed complete CS syndrome, with the right CN VI being the first to be affected. MRI revealed an irregular enhancement lesion in right CS after contrast administration. All patients died despite treatment. Conclusions: In patients with painful ophthalmoplegia, the most common hypotheses are diabetic neuropathy and Tolosa-Hunt syndrome. CS involvement may be the first evidence of a distant head and neck disease. Despite the poor prognosis, palliative care should be considered.
5
Borges, Matheus Araújo, Isabel Cristina Borges de Menezes, Isabela Garcia Bessa, Gabrielly de Souza Correia, Maria Clara Rocha Elias Dib, Rafaela Joy Falcão, and Leslivan Ubiratan Moraes. "Sexual dysfunction associated with neurological disorders in men aged 19 to 44 years." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.164.
Full textAbstract:
Introduction: Male sexual dysfunction (DSM) is characterized by changes in qualitative or quantitative sexual capacity, manifested by changes in ejaculation, erection, and/or orgasm, in addition to the presence of pain or discomfort in sexual relations, and the main one of these is erectile dysfunction (ED). Objective: Review the literature on sexual dysfunction caused by neurological disorders, in men aged 19 to 44 years. Methodology: This is a narrative literature review. The collection of information about the theme was carried out through a search for scientific articles in the PubMed databases. The descriptions used in the search were “sexual dysfunction AND neurological disorders in men”, articles published in the last 5 years were considered. Results: Several neurological diseases with a very high correlation with DSM were found, such as: multiple sclerosis, ED being the main problem reported by patients, depression and its respective treatment, epilepsy, mainly associated with anxiety and depression, Parkinson’s disease, spinal cord injury, spina bifida, stroke and traumatic brain injury, especially when associated with diabetic neuropathy. Conclusion: DS is a very frequent problem in neurological diseases, therefore, there is a need for this theme not to be neglected by health professionals, emphasizing the importance of multidisciplinary treatment. Mersh Terms: Impotence, Male Sexual Impotence, Nervous System Disease.
6
Koehler-McNicholas, Sara R., Lori Danzl, and Lars Oddsson. "The Effect of a Lower-Limb Sensory Prosthesis on Balance and Gait in People With Peripheral Neuropathy." In 2017 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/dmd2017-3466.
Full textAbstract:
Peripheral neuropathy (PN), commonly caused by diabetes mellitus, is a debilitating condition that currently affects approximately 20 million Americans. Chronic symptoms of PN often involve pain and weakness of the lower limbs, with eventual sensation loss on the plantar surfaces of the feet. According to epidemiological studies, reduced foot sole sensation has been linked to decreased standing stability [1] and an increased risk of falling [2]. Consequently, cost-effective interventions are needed to improve balance and mobility in this population. A growing body of research suggests that vibrotactile cues delivered to sensate areas of the lower limb may be an effective way to provide information about foot sole pressure to PN patients who experience poor balance control. Indeed, sensory substitution devices that provide vibrotactile feedback have been shown to aid in balance and improve postural control in various patient populations [3–7]. However, none of these technologies have been based on measurements of foot pressure nor have they been used as a balance prosthesis. The goal of this study was to investigate the effect of a new external lower-limb sensory prosthesis, the Walkasins™, on the balance and gait of individuals with PN who experience balance problems [8]. Walkasins™ consist of two parts: a leg unit and a foot pad (Figure 1). The leg unit wraps around the lower leg of the user and contains electronics for reading foot pad pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user’s leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present. The leg unit has a power button, two status LEDs, and a reset button (not shown in Figure 1). Power is supplied by a rechargeable internal battery. The foot pad is a thin consumable sole insert that can be cut to size and fit into a regular shoe. The foot pad connects to the leg unit through a physical cable. In this study, subjects performed gait and balance assessments with and without the Walkasins™ turned on in order to determine its short-term effects.
Reports on the topic "DIABETIC NEUROPATHIC PAIN"
1
Xing, Ying, Hongping Liu, Yifei Wang, and Tiancai Wen. Effects of acupuncture on pain in diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0019.
Full textAbstract:
Review question / Objective: The purpose of this review is to determine the efficacy and safety of acupuncture on diabetic peripheral neuropathy (DPN) pain compared with analgesics or sham acupuncture.Randomized controlled trials are the only types of studies included in this review. Condition being studied: Diabetic peripheral neuropathy (DPN) is a common complication of type 1 and 2 diabetes. It is also the main cause of lower limb amputation and disability in patients with diabetes. Epidemiological evidence shows that up to 50% of patients with diabetes developed neuropathy during their long-term course of disease. The cause of DPN is not completely clear, but older age, longer diabetic duration and worse postprandial glucose control has been proved to be closely related to DPN. Distal symmetric polyneuropathy is the most typical manifestation of DPN, and about 10% to 30% of the affected patients may experience symptoms of neuropathic pain. Pain can be described as burning pain, electrical or stabbing sensations, parasthesiae, hyperasthesiae, and deep aching pain of the feet and lower limbs at night. This irreversible and unbearable pain greatly affects patients' sleep and quality of life.
2
Wang, Liqin, Zhaohong Gao, Xiangru Niu, Meiqi Yuan, Yan Li, Fei Wang, Chuang Guo, and Zhen Ren. Acupuncture for diabetic neuropathic pain: protocol for a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2020. http://dx.doi.org/10.37766/inplasy2020.9.0043.
Full text
3
Zheng, Ruo-xiang, Jia-wei Xu, Bi-yao Jiang, Wei Tang, Chun-li Lu, Xiao-yang Hu, and Jian-ping Liu. Mind-body therapies in traditional Chinese medicine for neuropathic pain: a systematic review of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0016.
Full textAbstract:
Review question / Objective: The purpose of this review is to comprehensively evaluate the effectiveness and safety on mind-body therapies of traditional Chinese medicine for neuropathic pain. Condition being studied: According to the definition by the International Association for the Study of Pain (IASP), neuropathic pain is a kind of pain caused by lesions or diseases affecting the somatosensory nervous system. It has brought considerable negative impacts on patients and society. Neuropathic pain is a prevalent disease and can be induced by a variety of clinical conditions such as spinal cord injury (prevalence rate: 53%), induced peripheral neuropathic pain (prevalence rate: 38%), diabetic peripheral neuropathic pain (prevalence rate: 10%-26%), chemotherapy postherpetic neuralgia (3.9-42.0/10,000 people per year), prosopalgia (3-5/10,000 people per year), and so on. However, current recommended medicines for neuropathic pain management could cause dependence and adverse events. Thus, alternatives would be helpful for both patients and clinicians. Mind-body therapy in traditional Chinese medicine (TCM) has a long history in clinical practice for relieving pain and their effectiveness has not been systematically reviewed.The purpose of this review is to comprehensively evaluate the effectiveness and safety on mind-body therapies of traditional Chinese medicine for neuropathic pain.
4
Lekhanya, Portia Keabetswe, and Kabelo Mokgalaboni. Exploring the effectiveness of vitamin B12 complex and alpha-lipoic acid as a treatment for diabetic neuropathy. Protocol for systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0167.
Full textAbstract:
Review question / Objective: Does Alpha-Lipoic acid increase the uptake of glucose for better glycaemic control? Does vitamin B12 and Alpha-Lipoic acid improve inflammation? The aim of the study is to explore the effectiveness of Vitamin B12 and Alpha-Lipoic Acid as a possible treatment for diabetic neuropathy with major emphasis on markers of inflammation and glucose metabolism. Condition being studied: Diabetic Neuropathy (DN) is a heterogeneous type of nerve damage associated with diabetes mellitus, the condition most often damages nerves in the legs and feet. It presents both clinically and sub-clinically affecting the peripheral nervous system as a result of an increase in glucose concentration which interferes with nerve signalling. After the discovery of insulin as a treatment for Diabetes Mellitus (DM), the prevalence of DN has since increased significantly due to DM patients having a longer life expectancy. It has been estimated that atleast 50% of DM patients will develop DN in their life, with approximately 20% of these patients experiencing neuropathic pain. Nerves are susceptible to changes in glucose concentrations and insulin makes it impossible for neurons to continue regulating glucose uptake.
5
Lu, Qi, Haili Wang, Weizheng Wang, Yu Gao, Xuefeng Li, Ying Wang, Weiwan Yang, and Hongfeng Wang. Efficacy of Electroacupuncture in Painful Diabetic Peripheral Neuropathy: A protocol of systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0040.
Full textAbstract:
Review question / Objective: The aim of this study is to perform a meta-analysis to evaluate the effectiveness of electroacupuncture in the treatment of painful diabetic peripheral neuropathy (PDNP).And to provide data support for electroacupuncture as an effective means to treat pain of nervous system diseases. Condition being studied: Diabetes mellitus (DM) affects more than six hundred million population worldwide till 2045. The most common form is chronic, distal, and symmetric sensorimotor polyneuropathy, while other uncommon forms include asymmetric or focal neuropathy, such as diabetic muscle atrophy, trunk radiculopathy, and compression palsy. About 11.4% and 40.5% of patients have severe and moderate pain respectively. Currently, symptomatic treatment of PDPN is based on the application of medications that target the symptoms of PDPN. However, the clinical efficacy of PDPN patients varies greatly from individual to individual.Traditional Chinese medicine electroacupuncture have shown its unique advantages in the treatment of PDPN. Although its mechanism is complex and unclear, it can still be used in the clinical treatment of PDPN for a long time. We therefore present a systematic review of the benefits of electroacupuncture in improving PDPN by including the as many as possible randomized controlled trials.